Several studies have shown that various HDAC inhibitors such as SAHA and other hydroxamic acid derivatives increase cisplatin toxicity in cancer cells or can circumvent cisplatin resistance [39,40,41,42,43], supporting the association between the activity of cisplatin or carboplatin and the expression of HDAC2. Here, HDAC2 is linked to cancer.